| Year |
Citation |
Score |
| 2023 |
Oumedjbeur K, Corsi NJ, Bouhadana D, Ibrahim A, Nguyen DD, Matta I, Arezki A, Sadri I, Elsherbini T, Bhojani N, Elterman DS, Chughtai B, Helfand BT, Glaser AP, Misrai V, et al. Aquablation versus TURP: 5-year outcomes of the WATER randomized clinical trial for prostate volumes 50-80 mL. The Canadian Journal of Urology. 30: 11650-11658. PMID 37838991 |
0.315 |
|
| 2023 |
Kearns JT, Helfand BT. Is Active Surveillance Too Active? Current Urology Reports. PMID 37436691 DOI: 10.1007/s11934-023-01177-2 |
0.329 |
|
| 2023 |
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF. Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). European Urology. PMID 37414702 DOI: 10.1016/j.eururo.2023.06.018 |
0.315 |
|
| 2023 |
Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology. PMID 36609003 DOI: 10.1016/j.eururo.2022.12.021 |
0.308 |
|
| 2022 |
Wei J, Beebe-Dimmer J, Shi Z, Sample C, Yan G, Rifkin AS, Sadeghpour A, Gielzak M, Choi S, Moon D, Zheng SL, Helfand BT, Walsh PC, Xu J, Cooney KA, et al. Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry. The Prostate. PMID 36567534 DOI: 10.1002/pros.24477 |
0.362 |
|
| 2022 |
Glaser A, Shi Z, Wei J, Lanman NA, Ladson-Gary S, Vickman RE, Franco OE, Crawford SE, Lilly Zheng S, Hayward SW, Isaacs WB, Helfand BT, Xu J. Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer. European Urology Open Science. 43: 54-61. PMID 36353071 DOI: 10.1016/j.euros.2022.07.004 |
0.365 |
|
| 2022 |
Kearns JT, Helfand BT, Xu J. Moving Prostate Cancer Polygenic Risk Scores from Research Towards Clinical Practice. European Urology Focus. PMID 36055957 DOI: 10.1016/j.euf.2022.08.011 |
0.344 |
|
| 2022 |
Helfand BT, Paterakos M, Wang CH, Talaty P, Abran J, Bennett J, Hall DW, Lehman A, Aboushwareb T. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer. Plos One. 17: e0273782. PMID 36048818 DOI: 10.1371/journal.pone.0273782 |
0.328 |
|
| 2022 |
Andolfi C, Vickers AJ, Cooperberg MR, Carroll PR, Cowan JE, Paner GP, Helfand BT, Liauw SL, Eggener SE. Blood prostate-specific antigen by volume of benign, Gleason pattern 3 and 4 prostate tissue. Urology. PMID 35987380 DOI: 10.1016/j.urology.2022.08.014 |
0.307 |
|
| 2022 |
Helfand BT, Kasraeian A, Sterious S, Glaser AP, Talaty P, Alcantara M, Alcantara KM, Higgins A, Ghiraldi E, Elterman DS. How I do it: Aquablation in very large prostates (> 150 mL). The Canadian Journal of Urology. 29: 11111-11115. PMID 35429430 |
0.322 |
|
| 2022 |
Xu J, Resurreccion WK, Shi Z, Wei J, Wang CH, Zheng SL, Hulick PJ, Ross AE, Pavlovich CP, Helfand BT, Isaacs WB. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer and Prostatic Diseases. PMID 35347252 DOI: 10.1038/s41391-021-00458-6 |
0.353 |
|
| 2022 |
Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, ... ... Helfand BT, et al. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. Hgg Advances. 3. PMID 34993496 DOI: 10.1016/j.xhgg.2021.100070 |
0.335 |
|
| 2021 |
Helfand BT, Glaser AP, Kasraeian A, Sterious S, Talaty P, Alcantara M, Alcantara KM, Higgins A, Ghiraldi E, Elterman D. Men with lower urinary tract symptoms secondary to BPH undergoing Aquablation with very large prostates (> 150 mL). The Canadian Journal of Urology. 28: 10884-10888. PMID 34895392 |
0.339 |
|
| 2021 |
Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, ... ... Helfand BT, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. The Lancet. Oncology. PMID 34678156 DOI: 10.1016/S1470-2045(21)00522-2 |
0.334 |
|
| 2021 |
Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Pavlovich CP, Chan JM, Morgan TM, Klein EA, ... ... Helfand BT, et al. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. The Journal of Urology. 101097JU000000000000. PMID 34503355 DOI: 10.1097/JU.0000000000001937 |
0.338 |
|
| 2021 |
Wei J, Yang W, Shi Z, Lu L, Wang Q, Resurreccion WK, Engelmann V, Zheng SL, Hulick PJ, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. The Prostate. PMID 34254341 DOI: 10.1002/pros.24195 |
0.327 |
|
| 2021 |
Xu J, Isaacs WB, Mamawala M, Shi Z, Landis P, Petkewicz J, Wei J, Wang CH, Resurreccion WK, Na R, Bhanji Y, Novakovic K, Walsh PC, Zheng SL, Helfand BT, et al. Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. The Prostate. PMID 33956350 DOI: 10.1002/pros.24140 |
0.344 |
|
| 2020 |
Black MH, Li S, LaDuca H, Lo MT, Chen J, Hoiness R, Gutierrez S, Tippin-Davis B, Lu HM, Gielzak M, Wiley K, Shi Z, Wei J, Zheng SL, Helfand BT, et al. Validation of a prostate cancer polygenic risk score. The Prostate. 80: 1314-1321. PMID 33258481 DOI: 10.1002/Pros.24058 |
0.418 |
|
| 2020 |
Wei J, Shi Z, Na R, Wang CH, Resurreccion WK, Zheng SL, Hulick PJ, Cooney KA, Helfand BT, Isaacs WB, Xu J. Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. British Journal of Cancer. PMID 32830201 DOI: 10.1038/S41416-020-01036-8 |
0.377 |
|
| 2020 |
Liu W, Hou J, Petkewicz J, Na R, Wang CH, Sun J, Gallagher J, Bogachkov YY, Swenson L, Regner M, Resurreccion WK, Isaacs WB, Brendler CB, Crawford S, Zheng SL, ... Helfand BT, et al. Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression. The Prostate. PMID 32803894 DOI: 10.1002/Pros.24057 |
0.366 |
|
| 2020 |
Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, MacInnis RJ, Southey MC, Nguyen-Dumont T, Cancel-Tassin G, Cussenot O, Whittemore AS, Sieh W, Ioannidis NM, Hsieh CL, ... ... Helfand B, et al. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European Urology. PMID 32800727 DOI: 10.1016/J.Eururo.2020.07.038 |
0.463 |
|
| 2020 |
Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, ... ... Helfand BT, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000046. PMID 32516092 DOI: 10.1200/Jco.20.00046 |
0.429 |
|
| 2020 |
Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, Jackson M, Dolinsky JS, LaDuca H, Xu J, Black MH, Helfand BT. Diagnosing hereditary cancer predisposition in men with prostate cancer. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32439974 DOI: 10.1038/S41436-020-0830-5 |
0.462 |
|
| 2020 |
Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, Gielzak M, Na R, Sarver BAJ, Helfand BT, Walsh PC, Lotan TL, Cooney KA, Black MH, Xu J, et al. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology. PMID 31948886 DOI: 10.1016/J.Euo.2019.12.003 |
0.385 |
|
| 2020 |
Huang D, Wu YS, Ye DW, Qi J, Liu F, Helfand BT, Zheng SL, Ding Q, Xu DF, Na R, Xu JF, Sun YH. Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. Asian Journal of Andrology. PMID 31929198 DOI: 10.4103/Aja.Aja_136_19 |
0.457 |
|
| 2020 |
Wu Y, Yu H, Li S, Wiley K, Zheng S, LaDuca H, Gielzak M, Na R, Sarver B, Helfand* B, Walsh P, Lotan T, Cooney K, Black M, Xu J, et al. PD52-04 RARE GERMLINE PATHOGENIC MUTATIONS OF DNA REPAIR GENES ARE MOST STRONGLY ASSOCIATED WITH GRADE GROUP 5 PROSTATE CANCER The Journal of Urology. 203: e1090-e1091. DOI: 10.1097/Ju.0000000000000954.04 |
0.37 |
|
| 2020 |
Richgels J, Wackerbarth J, Helfand B, Glaser A. Pd48-07 Clinical Use Of Prostate Health Index (Phi) For Detection Of Prostate Cancer In 3,318 Patients The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000942.07 |
0.425 |
|
| 2020 |
Wu Y, Wei J, Shi Z, Fantus R, Zheng S, Cooney K, Isaacs W, Helfand* B, Xu J. PD38-06 WHICH GERMLINE GENES SHOULD BE TESTED FOR ASSESSING PROSTATE CANCER RISK? RESULTS FROM A LARGE POPULATION OF UNSELECTED CASES AND CONTROLS FROM UK BIOBANK The Journal of Urology. 203: e803. DOI: 10.1097/Ju.0000000000000917.06 |
0.384 |
|
| 2020 |
Fantus R, Wang C, Richgels J, Glaser A, Helfand B. Mp09-04 Prostate Health Index Density (Phid) Is More Predictive Of Disease Re-Categorization Than Multiparametric Mri In Men Undergoing Active Surveillance The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000829.04 |
0.386 |
|
| 2020 |
Vickman R, Cresswell G, Lanman N, Broman M, Franco O, Helfand B, Glaser A, Katz L, Petkewicz J, Talaty P, Crawford S, Ratliff T, Hayward* S. MP06-11 CHARACTERIZATION OF INFLAMMATORY CELLS IN HUMAN BENIGN PROSTATIC HYPERPLASIA The Journal of Urology. 203: e55. DOI: 10.1097/Ju.0000000000000820.011 |
0.413 |
|
| 2020 |
Xu J, Helfand B. Genetic Risk Score Linked With Younger Age Diagnosis of Prostate Cancer Oncology Times. 42: 8. DOI: 10.1097/01.cot.0000658832.18056.12 |
0.318 |
|
| 2019 |
Na R, Labbate C, Yu H, Shi Z, Fantus RJ, Wang CH, Andriole GL, Isaacs WB, Zheng SL, Helfand BT, Xu J. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. Jama Network Open. 2: e1918145. PMID 31880795 DOI: 10.1001/jamanetworkopen.2019.18145 |
0.327 |
|
| 2019 |
Vickman RE, Broman MM, Lanman NA, Franco OE, Sudyanti PAG, Ni Y, Ji Y, Helfand BT, Petkewicz J, Paterakos MC, Crawford SE, Ratliff TL, Hayward SW. Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. The Prostate. PMID 31763714 DOI: 10.1002/Pros.23929 |
0.421 |
|
| 2019 |
Yu H, Shi Z, Lin X, Bao Q, Jia H, Wei J, Helfand BT, Zheng SL, Duggan D, Lu D, Mo Z, Xu J. Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment. The Prostate. PMID 31634418 DOI: 10.1002/Pros.23920 |
0.342 |
|
| 2019 |
Helfand BT, Xu J. Germline testing for prostate cancer prognosis: implications for active surveillance. The Canadian Journal of Urology. 26: 48-49. PMID 31629432 |
0.355 |
|
| 2019 |
Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Mahle L, Grindedal EMM, James P, ... ... Helfand BT, et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology. PMID 31537406 DOI: 10.1016/J.Eururo.2019.08.019 |
0.415 |
|
| 2019 |
Xu J, Labbate CV, Isaacs WB, Helfand BT. Inherited risk assessment of prostate cancer: it takes three to do it right. Prostate Cancer and Prostatic Diseases. PMID 31417171 DOI: 10.1038/S41391-019-0165-Y |
0.44 |
|
| 2019 |
Lin X, Helfand BT, Xu J. Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.01.050. European Urology. PMID 31248607 DOI: 10.1016/J.Eururo.2019.06.013 |
0.347 |
|
| 2019 |
Victorson D, Schalet BD, Kundu S, Helfand BT, Novakovic K, Penedo F, Cella D. Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety. Cancer. PMID 31090933 DOI: 10.1002/Cncr.32189 |
0.357 |
|
| 2019 |
Shi Z, Yu H, Wu Y, Lin X, Bao Q, Jia H, Perschon C, Duggan D, Helfand BT, Zheng SL, Xu J. Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts. Cancer Medicine. PMID 30968590 DOI: 10.1002/Cam4.2143 |
0.335 |
|
| 2019 |
Labbate* C, Shi Z, Black MH, Li S, Laduca H, Wang C, Yu H, Helfand B, Isaacs W, Xu J. PD64-12 GENETIC RISK SCORE PREDICTS EARLY AGE-OF-ONSET OF PROSTATE CANCER Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557451.76634.B7 |
0.395 |
|
| 2019 |
Labbate C, Wang C, Novakovic K, Petkewicz J, Chang C, Helfand BT, Xu J. Pd50-07 Germline Genetic Risk Factors Help Predict Biopsy Upgrade During Active Surveillance Of Prostate Cancer The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556882.70456.0C |
0.406 |
|
| 2019 |
Black MH, Li S, LaDuca H, Gutierrez S, Lu H, Helfand* BT, Isaacs WB, Xu J. PD30-02 GERMLINE GENETIC ASSOCIATIONS WITH HIGH-RISK PROSTATE CANCER AND AGE AT DIAGNOSIS Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556134.36362.7E |
0.445 |
|
| 2018 |
Fantus RJ, Helfand BT. Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools. Clinical Chemistry. PMID 30459162 DOI: 10.1373/Clinchem.2018.286658 |
0.43 |
|
| 2018 |
Fantus RJ, Helfand BT. Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools. Clinical Chemistry. PMID 30459162 DOI: 10.1373/clinchem.2018.286658 |
0.319 |
|
| 2018 |
Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, et al. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European Urology. PMID 30309687 DOI: 10.1016/J.Eururo.2018.09.021 |
0.434 |
|
| 2018 |
Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, et al. Germline mutations in PPFIBP2 are associated with lethal prostate cancer. The Prostate. PMID 30043417 DOI: 10.1002/Pros.23697 |
0.448 |
|
| 2018 |
Helfand BT, Chen H, Fantus RJ, Conran CA, Brendler CB, Zheng SL, Walsh PC, Isaacs WB, Xu J. Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score. The Prostate. PMID 29923209 DOI: 10.1002/Pros.23664 |
0.387 |
|
| 2018 |
Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Selkirk CH, Davidson R, Longmuir M, et al. The psychosocial impact of undergoing prostate cancer screening for men with BRCA1/2 mutations. Bju International. PMID 29802810 DOI: 10.1111/Bju.14412 |
0.417 |
|
| 2018 |
Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, et al. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. The Prostate. PMID 29520813 DOI: 10.1002/Pros.23505 |
0.42 |
|
| 2018 |
Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, ... ... Helfand BT, et al. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer. PMID 29509747 DOI: 10.1038/bjc.2018.11 |
0.339 |
|
| 2018 |
Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, ... ... Helfand BT, et al. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer. PMID 29301143 DOI: 10.1038/Bjc.2017.429 |
0.46 |
|
| 2018 |
Zhang Q, Helfand B, Yang X, Carneiro B, Giles FJ, Kuzel T, Lee C, Cristofanilli M. Abstract 2553: PSMA-specific, TGF-ß-insensitive CD8+ T cells derived from metastatic castration resistant prostate cancer (mCRPC) patients induce apoptosis of PSMA positive prostate cancer (PCa) Immunology. 78: 2553-2553. DOI: 10.1158/1538-7445.Am2018-2553 |
0.304 |
|
| 2018 |
Barashi NS, Golan S, Wang C, Hirschhorn K, Petkewicz J, Silvers R, Thakrar K, Eggener SE, Helfand BT. MP12-14 MODELS INTEGRATING MRI PREDICT PROSTATE CANCER UPGRADING ON CONFIRMATORY BIOPSY IN ACTIVE SURVEILLANCE PATIENTS Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.401 |
0.418 |
|
| 2018 |
Na R, Wu Y, Zheng SL, Helfand B, Wang C, Brendler CB, Andriole GL, Xu J. MP35-12 GENETIC RISK SCORES ARE ASSOCIATED WITH EARLY AGE OF PROSTATE CANCER DIAGNOSIS: RESULTS FROM THE REDICE TRIAL Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1125 |
0.43 |
|
| 2018 |
Pritzlaff M, Allen K, LaDuca H, Fantus R, Helfand B. MP34-18 PERFORMANCE OF MULTIGENE PANEL TESTING IN HEREDITARY PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1110 |
0.438 |
|
| 2018 |
Carter HB, Mamawala M, Landis T, Wiley K, William B. I, Helfand B, Yu H, Wu Y, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, McGuire M, et al. PD20-04 GERMLINE MUTATIONS IN DNA REPAIR GENES ARE INDEPENDENT PREDICTORS OF GRADE RECLASSIFICATION IN ACTIVE SURVEILLANCE FOR PROSTATE CANCER PATIENTS Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1008 |
0.375 |
|
| 2017 |
Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. European Urology. PMID 29275833 DOI: 10.1016/J.Eururo.2017.12.008 |
0.348 |
|
| 2017 |
Chen H, Na R, Packiam VT, Conran CA, Jiang D, Tao S, Yu H, Lin X, Meng W, Zheng SL, Brendler CB, Helfand BT, Xu J. Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial. The Prostate. PMID 28670847 DOI: 10.1002/Pros.23369 |
0.333 |
|
| 2017 |
Na R, Ye D, Qi J, Liu F, Helfand BT, Brendler CB, Conran CA, Packiam V, Gong J, Wu Y, Zheng SL, Mo Z, Ding Q, Sun Y, Xu J. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. The Prostate. PMID 28664580 DOI: 10.1002/Pros.23382 |
0.442 |
|
| 2017 |
Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The Prostate. PMID 28656603 DOI: 10.1002/Pros.23380 |
0.426 |
|
| 2017 |
Helfand BT, Conran CA, Xu J, Catalona WJ. A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations. Current Opinion in Urology. PMID 28614085 DOI: 10.1097/Mou.0000000000000418 |
0.473 |
|
| 2017 |
Zhang Q, Kuzel T, Helfand B, Yang XJ, Qin W, Lee C, Carneiro B, Giles FJ. Abstract 5585: TGF-ß insensitive PSMA-specific CD8+ T cells derived from metastatic castration resistant prostate cancer (MCRPC) patients enhance the tumor killing ability Cancer Research. 77: 5585-5585. DOI: 10.1158/1538-7445.Am2017-5585 |
0.305 |
|
| 2017 |
Zhang Q, Kuzel T, Helfand B, Yang XJ, Qin W, Lee C, Carneiro B, Giles FJ. MP83-04 SUPPRESSION OF HUMAN PROSTATE CANCER (CAP) BY ADOPTIVE TRANSFER OF PATIENT-DERIVED PSMA-SPECIFIC, TGF-ß-INSENSITIVE CD8+ T CELLS Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2572 |
0.4 |
|
| 2017 |
Na R, S. Lilly SL, Han M, Yu H, Jiang D, Shah S, Ewing C, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth Jr D, Quinn M, Humphries E, Wiley K, ... ... Helfand B, et al. MP57-01 GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1775 |
0.391 |
|
| 2017 |
Zheng SL, Na R, Han M, Novakovic K, Wiley K, Isaacs S, Partin A, McGuire M, Walsh P, Brendler C, Helfand B, Isaacs W, Xu J. CHEK2
MUTATIONS INCREASE RISK FOR PROSTATE CANCER BUT DO NOT DIFFERENTIATE RISK OF LETHAL FROM INDOLENT DISEASE Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1573 |
0.406 |
|
| 2017 |
Adamsky M, Tallman J, Kuchta K, Helfand B. MP43-03 DO PROSTATE BIOPSY-ASSOCIATED COMPLICATIONS INFLUENCE TREATMENT SELECTION FOR PATIENTS WITH NEWLY DIAGNOSED, CLINICALLY LOCALIZED PROSTATE CANCER? Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1313 |
0.456 |
|
| 2017 |
Boysen WR, Rodriguez J, Kuchta K, Adamsky MA, Helfand BT, Park S. Pd24-06 Trends In Management Of Bone Health In Men With Metastatic Prostate Cancer: Analysis From The Surveillance, Epidemiology, And End Results Medicare Database The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1083 |
0.378 |
|
| 2017 |
Helfand B, Chen H, Na R, Conran C, Catalona W, Xu J. MP33-11 GENETIC RISK SCORE CAN DISTINGUISH RISK OF PROSTATE CANCER AMONG FAMILY MEMBERS WITH SIMILAR DEGREES OF RELATIONSHIP Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1007 |
0.404 |
|
| 2016 |
Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL, Quinn M, Humphries E, Wiley KE, ... ... Helfand BT, et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology. PMID 27989354 DOI: 10.1016/S1569-9056(17)30541-9 |
0.427 |
|
| 2016 |
Rudichuk L, Vogel KJ, Wang CH, Helfand BT, Selkirk CG. Urologists' Current Practices in Screening and Treating Men with a Family History of Prostate Cancer. Urology. PMID 27645528 DOI: 10.1016/J.Urology.2016.07.032 |
0.416 |
|
| 2016 |
Helfand BT, Kearns J, Conran C, Xu J. Clinical validity and utility of genetic risk scores in prostate cancer. Asian Journal of Andrology. PMID 27297129 DOI: 10.4103/1008-682X.182981 |
0.363 |
|
| 2016 |
Victorson DE, Schuette S, Schalet BD, Kundu SD, Helfand BT, Novakovic K, Sufrin N, McGuire M, Brendler C. Factors Affecting Quality of Life at Different Time Points since Treatment in a Sample of Men with Localized Prostate Cancer: The Unique Influence of Treatment Decision Making Satisfaction, Personality, and Sexual Functioning. The Journal of Urology. PMID 27259651 DOI: 10.1016/J.Juro.2016.05.099 |
0.389 |
|
| 2016 |
Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, et al. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. The Prostate. PMID 27197965 DOI: 10.1002/Pros.23200 |
0.429 |
|
| 2016 |
Cohen A, Lapin B, Wang CH, Helfand B, Victorson D, Novakovic K. Variation in Testosterone Levels and Health Related Quality of Life in Men Diagnosed with Prostate Cancer on Active Surveillance. Urology. PMID 27179775 DOI: 10.1016/J.Urology.2016.03.056 |
0.394 |
|
| 2016 |
Na R, Ye D, Qi J, Liu F, Lin X, Helfand BT, Brendler CB, Conran C, Gong J, Wu Y, Gao X, Chen Y, Zheng SL, Mo Z, Ding Q, et al. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases. Asian Journal of Andrology. PMID 27140652 |
0.315 |
|
| 2016 |
Helfand BT. A comparison of genetic risk score with family history for estimating prostate cancer risk. Asian Journal of Andrology. PMID 27004541 DOI: 10.4103/1008-682X.177122 |
0.371 |
|
| 2016 |
Selkirk CG, Helfand BT. To PSA or not to PSA? Still a question for men with a family history of prostate cancer. Bju International. 117: 545. PMID 26969030 DOI: 10.1111/Bju.13372 |
0.451 |
|
| 2016 |
Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, Simko JP, Ngo V, Chen Y, Levin AM, Chitale D, Helfand BT, Catalona WJ, Rybicki BA, Witte JS. Mutational landscape of aggressive prostate tumors in African American men. Cancer Research. PMID 26921337 DOI: 10.1158/0008-5472.Can-15-1787 |
0.433 |
|
| 2016 |
Stacey SN, Kehr B, Gudmundsson J, Zink F, Jonasdottir A, Gudjonsson SA, Sigurdsson A, Halldorsson BV, Agnarsson BA, Benediktsdottir KR, Aben KK, Vermeulen SH, Cremers RG, Panadero A, Helfand BT, et al. Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. Human Molecular Genetics. PMID 26740556 DOI: 10.1093/Hmg/Ddv622 |
0.392 |
|
| 2016 |
Na R, Ye D, Qi J, Liu F, Lin X, Helfand B, Brendler C, Conran C, Gong J, Wu Y, Gao X, Chen Y, Zheng S, Mo Z, Ding Q, et al. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases Asian Journal of Andrology. 18: 525-529. DOI: 10.4103/1008-682X.179857 |
0.315 |
|
| 2016 |
Jiang D, Chen H, Helfand B, Conran C, Zheng SL, Brendler C, Xu J. MP90-12
INHERITED RISK FOR OTHER TYPES OF CANCER AMONG MEN WITH OR WITHOUT PROSTATE CANCER BASED ON THE GENETIC RISK SCORE Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2556 |
0.385 |
|
| 2016 |
Chen H, Packiam VT, Helfand BT, Conran CA, Zheng SL, Isaacs WB, Brendler CB, Xu J. MP07-08 THE PLATEAU EFFECT OF NUMBER OF PROSTATE CANCER RISK-ASSOCIATED SINGLE NUCLEOTIDE POLYMORPHISMS USED TO ASSESS GENETIC RISK Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2211 |
0.417 |
|
| 2016 |
Pruitt J, Petkewicz J, Lapin B, Franco OE, Helfand BT, Brendler CB, Wang C, Hayward SW. MP35-02
BENIGN PROSTATIC HYPERPLASIA AND AUTOIMMUNE INFLAMMATORY DISEASES COINCIDENCE AND CONSEQUENCES Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1594 |
0.362 |
|
| 2016 |
Helfand BT, Packiam VT, Chen H, Zheng SL, Conran CA, Brendler CB, Isaacs WB, Xu J. PD15-06
GENETIC RISK SCORE DIFFERENTIATES INHERITED RISK AMONG RELATIVES OF PATIENTS WITH HEREDITARY PROSTATE CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1132 |
0.356 |
|
| 2015 |
Pearce SM, Wang CH, Victorson DE, Helfand BT, Novakovic KR, Brendler CB, Albaugh JA. A Longitudinal Study of Predictors of Sexual Dysfunction in Men on Active Surveillance for Prostate Cancer. Sexual Medicine. 3: 156-64. PMID 26468379 DOI: 10.1002/Sm2.78 |
0.357 |
|
| 2015 |
Kearns JT, Lapin B, Wang E, Roehl KA, Cooper P, Catalona WJ, Helfand BT. Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer. European Urology. PMID 26411806 DOI: 10.1016/J.Eururo.2015.09.004 |
0.42 |
|
| 2015 |
Helfand BT. Temporary erectile dysfunction after prostate biopsy. Bju International. 116: 164. PMID 26202006 DOI: 10.1111/Bju.13022 |
0.434 |
|
| 2015 |
Anderson BB, Pariser JJ, Helfand BT. Comparison of Patients Undergoing PVP Versus TURP for LUTS/BPH. Current Urology Reports. 16: 525. PMID 26077354 DOI: 10.1007/S11934-015-0525-7 |
0.434 |
|
| 2015 |
Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, et al. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Human Genetics. 134: 439-50. PMID 25715684 DOI: 10.1007/S00439-015-1534-9 |
0.372 |
|
| 2015 |
Selkirk CG, Wang CH, Lapin B, Helfand BT. Family history of prostate cancer in men being followed by active surveillance does not increase risk of being diagnosed with high-grade disease. Urology. 85: 742-7. PMID 25709045 DOI: 10.1016/J.Urology.2014.10.060 |
0.425 |
|
| 2015 |
Roy HK, Brendler CB, Subramanian H, Zhang D, Maneval C, Chandler J, Bowen L, Kaul KL, Helfand BT, Wang CH, Quinn M, Petkewicz J, Paterakos M, Backman V. Nanocytological field carcinogenesis detection to mitigate overdiagnosis of prostate cancer: a proof of concept study. Plos One. 10: e0115999. PMID 25706755 DOI: 10.1371/Journal.Pone.0115999 |
0.45 |
|
| 2015 |
Helfand BT, Catalona WJ, Xu J. A genetic-based approach to personalized prostate cancer screening and treatment. Current Opinion in Urology. 25: 53-8. PMID 25405931 DOI: 10.1097/Mou.0000000000000130 |
0.424 |
|
| 2015 |
Malik RD, Wang CE, Lapin B, Gerber GS, Helfand BT. Comparison of patients undergoing laser vaporization of the prostate versus TURP using the ACS-NSQIP database. Prostate Cancer and Prostatic Diseases. 18: 18-24. PMID 25311768 DOI: 10.1038/Pcan.2014.39 |
0.376 |
|
| 2015 |
Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT. A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease. Bju International. 115: 101-5. PMID 24952954 DOI: 10.1111/Bju.12847 |
0.768 |
|
| 2015 |
Mikropoulos C, Selkirk C, Saya S, Bancroft E, Dadaev T, Brendler C, Saunders E, Leongamornlert D, Page E, Borrella CC, study Collaborators And Steering Gr TI, Moss S, Kote-Jarai Z, Helfand B, Eeles RA. Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study (IMPACT study). Journal of Clinical Oncology. 33: 16-16. DOI: 10.1200/Jco.2015.33.7_Suppl.16 |
0.433 |
|
| 2015 |
Selkirk C, Mikropoulos C, Saya S, Bancroft E, Dadaev T, Brendler C, Page E, Leongamornlert D, Taylor N, Saunders E, Cieza-Borrela C, Dias AET, Moss S, Kote-Jarai Z, Helfand B, et al. 2574 Prostate-Specific Antigen velocity as a predictive biomarker in a prospective prostate cancer screening study of men with genetic predisposition European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31393-4 |
0.449 |
|
| 2015 |
Cohen AJ, Pariser JJ, Lapin B, Wang C, Helfand BT, McGuire M. MP14-18 VERY LOW RISK VS. LOW RISK PROSTATE CANCER DESIGNATIONS IN AN ACTIVE SURVEILLANCE COHORT Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.880 |
0.435 |
|
| 2015 |
Victorson D, Sufrin N, Helfand BT, Novakovic KR, Pariser JJ, McGuire M, Brendler C. PD47-11 PREDICTORS OF QUALITY OF LIFE IN MEN WITH LOCALIZED PROSTATE CANCER: THE ROLE OF TREATMENT DECISION MAKING SATISFACTION, NEUROTICISM, AND SEXUAL FUNCTIONING Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2755 |
0.369 |
|
| 2015 |
Kearns J, Helfand B, Roehl K, Novakovic K, Cooper P, Catalona W. PD38-07 GENETIC CORRECTION OF PSA CAN REDUCE THE NUMBER OF MEN DIAGNOSED WITH POTENTIALLY INSIGNIFICANT PROSTATE CANCER: RESULTS FROM A SURGICAL AND ACTIVE SURVEILLANCE COHORT Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2428 |
0.429 |
|
| 2015 |
Selkirk CG, Mikropoulos C, Saya S, Bancroft E, Dadaev T, Brendler C, Page E, Leongamornlert DA, Taylor N, Saunders EJ, Cieza-Borrela C, study collaborators TI, Moss S, Kote-Jarai Z, Helfand BT, et al. MP86-11 PROSTATE SPECIFIC ANTIGEN VELOCITY AS A PREDICTIVE BIOMARKER IN A PROSPECTIVE PROSTATE CANCER SCREENING STUDY OF MEN WITH GENETIC PREDISPOSITION Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1920 |
0.45 |
|
| 2015 |
Kearns J, Helfand B, Brendler C, Roy H, Wang C, Novakovic K, Subramanian H, Zhang D, Maneval C, Backman V. MP1-20 DISTINGUISHING INDOLENT FROM AGGRESSIVE PROSTATE CANCER IN ACTIVE SURVEILLANCE USING PARTIALWAVE SPECTROSCOPY TO MEASURE NANOCYTOLOGICAL FIELD CARCINOGENESIS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.183 |
0.465 |
|
| 2014 |
Helfand BT, Catalona WJ. The epidemiology and clinical implications of genetic variation in prostate cancer. The Urologic Clinics of North America. 41: 277-97. PMID 24725490 DOI: 10.1016/J.Ucl.2014.01.001 |
0.417 |
|
| 2014 |
Donin NM, Loeb S, Cooper PR, Roehl KA, Baumann NA, Catalona WJ, Helfand BT. Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men. Bju International. 114: E50-5. PMID 24712975 DOI: 10.1111/Bju.12647 |
0.41 |
|
| 2014 |
Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, Loeb S. Prostate cancer risk alleles are associated with prostate cancer volume and prostate size. The Journal of Urology. 191: 1733-6. PMID 24345439 DOI: 10.1016/J.Juro.2013.12.030 |
0.482 |
|
| 2014 |
Cohn JA, Dangle PP, Wang CE, Brendler CB, Novakovic KR, McGuire MS, Helfand BT. The prognostic significance of perineural invasion and race in men considering active surveillance. Bju International. 114: 75-80. PMID 24106869 DOI: 10.1111/Bju.12463 |
0.358 |
|
| 2014 |
Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, McGuire MS, Helfand BT. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urologic Oncology. 32: 41.e23-30. PMID 23911680 DOI: 10.1016/J.Urolonc.2013.04.013 |
0.351 |
|
| 2014 |
McGuire BB, Anglim B, Loeb S, Helfand BT, Grainger R, Flynn R, McDermott T, Hu Q, Cooper PR, Fennell A, Catalona WJ, Thornhill J. Radical prostatectomy outcomes during prostate-specific antigen era in Ireland compared to a matched American population Journal of Clinical Urology. 7: 170-175. DOI: 10.1177/2051415813496995 |
0.384 |
|
| 2014 |
Zhang Q, Helfand B, Lin X, Jang T, Guo Y, Khandekar J, Kuzel TM, Lee C. Abstract 4038: Human prostate cancer invasion could be suppressed by 5-Aza-2′-deoxycytidine which can inhibit the TGF-β induced DNA methyltransferase (DNMT) Cancer Research. 74: 4038-4038. DOI: 10.1158/1538-7445.Am2014-4038 |
0.305 |
|
| 2014 |
Roy H, Brendler C, Subramanian H, Zhang D, Maneval C, Kaul K, Helfand B, Wang C, Paterakos M, Backman V. 647: Partial wave spectroscopic nanocytology to personalize management of early stage prostate cancer European Journal of Cancer. 50: S154. DOI: 10.1016/S0959-8049(14)50567-9 |
0.372 |
|
| 2014 |
Whittington A, Roehl KA, Scholtens D, Cooper P, Catalona WJ, Helfand BT. Mp79-03 Results Of The Nci Prostate Cancer Genetics Working Group Analysis Comparing 36 Validated Prostate Cancer Loci With Aggressive Disease The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2506 |
0.46 |
|
| 2014 |
Whittington A, Lapin B, Wang C, Helfand B, McGuire M. MP74-18 FINDINGS OF ASAP/PIN ARE ASSOCIATED WITH DISEASE PROGRESSION IN ACTIVE SURVEILLANCE Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2351 |
0.35 |
|
| 2014 |
Selkirk C, Hatcher D, Powers J, Hulick P, McGuire M, Brendler C, Helfand BT. Mp69-05 Psa Values And Kinetics Of Brca1 And Brca2 Mutation Carriers At High Risk For Prostate Cancer The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2224 |
0.39 |
|
| 2014 |
Malik R, Wang C, Lapin B, Helfand BT. PD26-07 COMPARISON OF PATIENTS UNDERGOING PHOTOVAPORIZATION OF THE PROSTATE VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2094 |
0.408 |
|
| 2014 |
Hatcher D, Wang C, Novakovic KR, Brendler C, McGuire M, Victorson D, Helfand BT. PD21-06 THE ROLE OF AGE AND PROSTATE CANCER ANXIETY ON URINARY SYMPTOMS IN MEN ON ACTIVE SURVEILLANCE Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1683 |
0.405 |
|
| 2013 |
Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ. Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. The Journal of Urology. 189: 1697-701. PMID 23246478 DOI: 10.1016/J.Juro.2012.12.023 |
0.449 |
|
| 2013 |
Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility. The Journal of Urology. 189: 845-8. PMID 23159463 DOI: 10.1016/J.Juro.2012.11.044 |
0.46 |
|
| 2013 |
Helfand BT, Glaser AP, Rimar K, Zargaroff S, Hedges J, McGuire BB, Catalona WJ, McVary KT. Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy. Bju International. 111: 38-43. PMID 22639942 DOI: 10.1111/J.1464-410X.2012.11268.X |
0.437 |
|
| 2013 |
Banks JA, McGuire BB, Loeb S, Shrestha S, Helfand BT, Catalona WJ. Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy. Urologic Oncology. 31: 1049-53. PMID 22285005 DOI: 10.1016/J.Urolonc.2011.12.008 |
0.343 |
|
| 2013 |
Helfand BT, Loeb S, Roehl KA, Reinhardt D, Cooper PR, Catalona WJ. 989 A RARE GENETIC VARIANT ON CHROMOSOME 8Q24 THAT CONFERS A SIGNIFICANTLY GREATER RISK OF PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.571 |
0.468 |
|
| 2013 |
Helfand BT, Loeb S, Roehl KA, Reinhardt D, Cooper PR, Hu Q, Catalona WJ. 984 Association Between Prostate Cancer Single Nucleotide Polymorphisms (Snps) And Aggressive Disease In The National Cancer Institute Genetics Working Group Cohort The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.566 |
0.414 |
|
| 2013 |
Quinn M, Novakovic K, Shumaker D, Rabbitt S, Pruitt J, Helfand B. 797 TRANSCELLULAR MIGRATION OF PROSTATE CANCER CELLS THROUGH ENDOTHELIAL CELLS REQUIRES VIMENTIN Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.361 |
0.437 |
|
| 2013 |
Novakovic K, Quinn M, Fitchev P, Cornwell M, Brendler C, McGuire M, Helfand B, Pruitt J, Rabbitt S, Plunkett B, Doll J, Lee C, Crawford S. 787 SHARED LIPID ENERGY: PROSTATE CANCER CELLS STIMULATE ADIPOCYTE MIGRATION
IN VITRO
AND
IN VIVO Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.351 |
0.41 |
|
| 2013 |
Zhang Q, Lin X, Helfand B, Lee B, Wang Z, Kuzel TM, Brendler CB, Catalona WJ, Guo Y, Chen L, Yang XJ, Jovanovic B, Lee C. 1613 EXTRACELLULAR SIGNAL-REGULATED KINASES IS AN IMPORTANT FACTOR INVOLVED IN THE DEVELOPMENT OF BENIGN PROSTATE Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.3163 |
0.38 |
|
| 2013 |
Helfand BT, Loeb S, Roehl KA, Reinhardt D, Cooper PR, McVary KT, Catalona WJ. 1740 GENETICS VARIANTS THAT INCREASE SEVERE LOWER URINARY TRACT SYMPTOMS IN AFRICAN-AMERICAN MEN Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2910 |
0.363 |
|
| 2013 |
Albaugh J, Helfand B, Victorson D, Novakovic K, Brendler C, Pruitt J, Rabbitt S, McGuire M. 1396 WHAT PREDICTS LONG TERM SEXUAL DYSFUNCTION FOR MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER? Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2750 |
0.395 |
|
| 2013 |
Zhang Q, Lee B, Lin X, Helfand B, Wang Z, Dulude H, Panchal C, Slovin S, Kozlowski J, Sivolapenko G, Kuzel TM, Brendler CB, Catalona WJ, Guo Y, Chen L, et al. 1336 PCK3145 SUPPRESSES THE INVASIVE CAPABILITIES OF HUMAN PROSTATE CANCER CELLS INDUCED BY TRANSFORMING GROWTH FACTOR BETA Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2690 |
0.382 |
|
| 2013 |
Bjurlin MA, Roehl KA, Cooper P, Helfand BT, Hu Q, Catalona WJ, Loeb S. 2063 CHARACTERISTICS AND PREDICTORS OF PROSTATE NEEDLE BIOPSY COMPLIANCE Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2482 |
0.428 |
|
| 2013 |
Helfand BT, Loeb S, Roehl KA, Reinhardt D, Cooper PR, Catalona WJ. 2049 GENETIC ADJUSTMENT OF PSA VALUES IN AFRICAN-AMERICAN MEN REDUCES POTENTIALLY DELAYED BIOPSIES Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2468 |
0.435 |
|
| 2012 |
Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, Benediktsdottir KR, Sigurdsson A, Magnusson OT, Gudjonsson SA, Magnusdottir DN, Johannsdottir H, Helgadottir HT, Stacey SN, Jonasdottir A, Olafsdottir SB, ... ... Helfand BT, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nature Genetics. 44: 1326-9. PMID 23104005 DOI: 10.1038/Ng.2437 |
0.453 |
|
| 2012 |
Glaser AP, Novakovic K, Helfand BT. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Current Urology Reports. 13: 447-54. PMID 22935886 DOI: 10.1007/S11934-012-0277-6 |
0.414 |
|
| 2012 |
Sheth KR, Sharma V, Helfand BT, Cashy J, Smith K, Hedges JC, Köhler TS, Woodruff TK, Brannigan RE. Improved fertility preservation care for male patients with cancer after establishment of formalized oncofertility program. The Journal of Urology. 187: 979-86. PMID 22264454 DOI: 10.1016/J.Juro.2011.10.154 |
0.336 |
|
| 2012 |
Mazur DJ, Helfand BT, McVary KT. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men. The Urologic Clinics of North America. 39: 77-88. PMID 22118347 DOI: 10.1016/J.Ucl.2011.09.005 |
0.386 |
|
| 2012 |
McGuire BB, Helfand BT, Kundu S, Hu Q, Banks JA, Cooper P, Catalona WJ. Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance. Bju International. 110: 338-43. PMID 22077888 DOI: 10.1111/J.1464-410X.2011.10750.X |
0.46 |
|
| 2012 |
Helfand BT, Wang Y, Pfleghaar K, Shimi T, Taimen P, Shumaker DK. Chromosomal regions associated with prostate cancer risk localize to lamin B-deficient microdomains and exhibit reduced gene transcription. The Journal of Pathology. 226: 735-45. PMID 22025297 DOI: 10.1002/Path.3033 |
0.361 |
|
| 2012 |
McGuire BB, Helfand BT, Loeb S, Hu Q, O'Brien D, Cooper P, Yang X, Catalona WJ. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level. Bju International. 109: 1764-9. PMID 22017732 DOI: 10.1111/J.1464-410X.2011.10628.X |
0.451 |
|
| 2012 |
Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, ... ... Helfand BT, et al. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. The Prostate. 72: 410-26. PMID 21748754 DOI: 10.1002/Pros.21443 |
0.351 |
|
| 2012 |
Zhang Q, Lin X, Helfand B, Chen L, Kozlowski J, Yang XJ, Zhu LJ, Lee C. Abstract LB-294: Transforming growth factor beta 3 (TGF-ß3) contributes to epithelial-mesenchymal transitions (EMT) in human prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-294 |
0.362 |
|
| 2012 |
Hu Q, Helfand BT, Loeb S, Baumann N, Catalona WJ. 472 PROSTATE CANCER RISK ALLELES ARE PRESENT AT SIGNIFICANTLY DIFFERENT FREQUENCIES IN HEALTHY VOLUNTEERS OF DIFFERENT RACES Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.541 |
0.428 |
|
| 2012 |
McGuire BB, Helfand BT, Hu Q, Loeb S, Kim DY, Cooper PR, Hofer MD, Catalona WJ. 371 ARE GENETIC VARIANTS THAT PROMOTE PSA EXPRESSION ASSOCIATED WITH MORE FAVORABLE PATHOLOGIC TUMOR FEATURES Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.433 |
0.4 |
|
| 2012 |
Loeb S, Helfand BT, McGuire BB, Hu Q, Cooper PR, Hofer MD, Catalona WJ. 2224 PROSTATE CANCER RISK ALLELES ARE ASSOCIATED WITH PROSTATE CANCER TUMOR VOLUME BUT NOT PROSTATE SIZE Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2400 |
0.465 |
|
| 2012 |
Helfand BT, Hu Q, Loeb S, Kim DY, Cooper PR, Hofer MD, McGuire BB, McVary KT, Catalona WJ. 1725 GENETIC SEQUENCE VARIANTS ASSOCIATED WITH BOTH SEVERITY OF LOWER URINARY TRACT SYMPTOMS AND PROSTATE CANCER SUSCEPTIBILITY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1686 |
0.423 |
|
| 2012 |
Zhang Q, Chen L, Helfand B, Sharma V, Qin W, Yang XJ, Jovanovic B, Brendler CB, Guo Y, Catalona W, Lee C, Kozlowski J. 1310 SUPPRESSION OF CD8+ T CELL INFILTRATION BY INCREASED TGF-β EXPRESSION IS ASSOCIATED WITH BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS WITH LOW GLEASON SCORES Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1657 |
0.366 |
|
| 2012 |
Helfand BT, Loeb S, Hofer MD, Kim DY, Hu Q, Cooper PR, McGuire BB, Catalona WJ. 1209 PERSONALIZED PSA TESTING USING GENETIC VARIANTS CAN POSSIBLY DECREASE THE NUMBER OF PROSTATE BIOPSIES Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1498 |
0.4 |
|
| 2011 |
Zhang Q, Chen L, Helfand BT, Jang TL, Sharma V, Kozlowski J, Kuzel TM, Zhu LJ, Yang XJ, Javonovic B, Guo Y, Lonning S, Harper J, Teicher BA, Brendler C, et al. TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. Plos One. 6: e25168. PMID 21980391 DOI: 10.1371/Journal.Pone.0025168 |
0.369 |
|
| 2011 |
Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexø BA, Tjønneland A, Overvad K, ... ... Helfand BT, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics. 43: 1098-103. PMID 21946351 DOI: 10.1038/Ng.926 |
0.313 |
|
| 2011 |
Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, Catalona WJ. Prostate cancer risk alleles and their associations with other malignancies. Urology. 78: 970.e15-20. PMID 21820706 DOI: 10.1016/J.Urology.2011.05.035 |
0.439 |
|
| 2011 |
O'Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, Catalona WJ. Delay of surgery in men with low risk prostate cancer. The Journal of Urology. 185: 2143-7. PMID 21496847 DOI: 10.1016/J.Juro.2011.02.009 |
0.421 |
|
| 2011 |
Rebuck DA, Zhao LC, Helfand BT, Casey JT, Navai N, Perry KT, Nadler RB. Simple modifications in operating room processes to reduce the times and costs associated with robot-assisted laparoscopic radical prostatectomy. Journal of Endourology / Endourological Society. 25: 955-60. PMID 21457071 DOI: 10.1089/End.2010.0534 |
0.318 |
|
| 2011 |
Helfand BT, Mendez MG, Murthy SN, Shumaker DK, Grin B, Mahammad S, Aebi U, Wedig T, Wu YI, Hahn KM, Inagaki M, Herrmann H, Goldman RD. Vimentin organization modulates the formation of lamellipodia. Molecular Biology of the Cell. 22: 1274-89. PMID 21346197 DOI: 10.1091/Mbc.E10-08-0699 |
0.731 |
|
| 2011 |
Helfand BT, Kan D, Modi P, Catalona WJ. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination. The Prostate. 71: 394-402. PMID 20860009 DOI: 10.1002/Pros.21253 |
0.455 |
|
| 2011 |
Zhang Q, Chen L, Helfand B, Kozlowski J, Brendler CB, Kuzel TM, Lee C. Abstract LB-3: The recruitment of PP2A by TGF-β receptors mediates the response to TGF-β-induced activation of ERK in prostate cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-3 |
0.353 |
|
| 2011 |
Zhang Q, Helfand B, Chen L, Qin W, Zhang W, Brendler C, Jiang T, Kundu SD, Zhu L, Sharma V, Randall-London S, Lee B, Kuzel TM, Yang XJ, Jovanovic B, et al. 275 ANTI-TRANSFORMING GROWTH FACTOR-β ANTIBODY 1D11 SUPPRESSES THE INVASION OF HUMAN PROSTATE CANCER CELLS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.367 |
0.363 |
|
| 2011 |
Zhang Q, Helfand B, Chen L, Zhang W, Qin W, Brendler C, Jiang T, Kundu SD, Lee B, Sharma V, Zhu L, Jovanovic B, Yang XJ, Kuzel TM, Guo Y, et al. 274 TGF-β MEDIATES METHYLATION OF ITS RECEPTORS PROMOTER BY ACTIVATION OF DNA METHYLTRANSFERASE (DNMT) IN PROSTATE CANCER CELLS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.366 |
0.37 |
|
| 2011 |
Helfand BT, McGuire BB, Delli-Zotti KA, Catalona WJ. 2286 FREQUENCIES OF PROSTATE CANCER RISK VARIANTS IN EARLY ONSET AND FAMILIAL PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2531 |
0.457 |
|
| 2011 |
Helfand BT, McGuire BB, O'Brien DC, Catalona WJ. 2034 ASSOCIATION OF PROSTATE CANCER RISK ALLELES WITH PATHOLOGY UP-GRADING AT RADICAL PROSTATECTOMY Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2263 |
0.462 |
|
| 2011 |
Helfand BT, Hedges JC, Cashy J, McGuire BB, Catalona WJ, McVary KT. 1803 PROSTATE CANCER DIAGNOSIS IS ASSOCIATED WITH AN INCREASED RISK OF ERECTILE DYSFUNCTION FOLLOWING PROSTATE BIOPSY Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2175 |
0.469 |
|
| 2011 |
Helfand BT, Hofer MD, Hu Q, McGuire BB, O'Brien DC, Catalona WJ. 715 GENETIC RISK VARIANTS ON 8Q24 ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1683 |
0.434 |
|
| 2011 |
McGuire BB, O'Brien DC, Loeb S, Li C, Delli-Zotti KA, Helfand BT, Catalona WJ. 714 Outcomes In Patients With Gleason Score 8–10 Prostate Cancer: Relation To Pre-Operative Psa Level The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1682 |
0.416 |
|
| 2011 |
Helfand BT, Wang Y, Taiman P, Pfleghaar K, Goldman RD, Shumaker DK. 619 EPIGENETIC CONTROL OF ANDROGEN ENRICHED LAMIN DEFINED MICRODOMAINS (LDMDS) IN PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1472 |
0.612 |
|
| 2010 |
Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, Agnarsson BA, Benediktsdottir KR, Isaksson HJ, Kostic JP, Gudjonsson SA, Stacey SN, Gylfason A, Sigurdsson A, Holm H, ... ... Helfand BT, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Science Translational Medicine. 2: 62ra92. PMID 21160077 DOI: 10.1126/scitranslmed.3001513 |
0.312 |
|
| 2010 |
Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, Catalona WJ. Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. The Journal of Urology. 184: 501-5. PMID 20620408 DOI: 10.1016/J.Juro.2010.04.032 |
0.441 |
|
| 2010 |
Helfand BT, Loeb S, Kan D, Catalona WJ. Number of prostate cancer risk alleles may identify possibly 'insignificant' disease. Bju International. 106: 1602-6. PMID 20590552 DOI: 10.1111/J.1464-410X.2010.09440.X |
0.402 |
|
| 2010 |
Helfand BT, Blackwell RH, McVary KT. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. The Journal of Urology. 184: 218-23. PMID 20483154 DOI: 10.1016/J.Juro.2010.03.020 |
0.419 |
|
| 2010 |
Modi P, Helfand BT, McVary KT. Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Current Urology Reports. 11: 224-7. PMID 20467844 DOI: 10.1007/S11934-010-0113-9 |
0.44 |
|
| 2010 |
Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. European Urology. 57: 586-91. PMID 20036783 DOI: 10.1016/J.Eururo.2009.12.025 |
0.336 |
|
| 2010 |
Loeb S, Roehl KA, Helfand BT, Kan D, Catalona WJ. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? The Journal of Urology. 183: 112-6. PMID 19913814 DOI: 10.1016/J.Juro.2009.08.156 |
0.461 |
|
| 2010 |
Loeb S, Kan D, Helfand BT, Nadler RB, Catalona WJ. Is statin use associated with prostate cancer aggressiveness? Bju International. 105: 1222-5. PMID 19888973 DOI: 10.1016/S0022-5347(09)60590-5 |
0.46 |
|
| 2010 |
Zhang Q, Chen L, Helfand B, Zhu LJ, Smith N, Guo Y, Javonovic B, Lee C. Abstract LB-85: TGF-ß regulates its own expression and down-regulates its own receptors in prostate cancer (CaP) cells through a positive feedback pathway mediated by DNA methyltransferase Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-85 |
0.326 |
|
| 2010 |
Zhang Q, Chen L, Helfand B, Jang T, Guo Y, Lee C. Abstract 3185: Expression of DNA methyltransferase (DNMT) induced by transforming growth factor-ß (TGF-ß) promotes progress of prostate cancer Cancer Research. 70: 3185-3185. DOI: 10.1158/1538-7445.Am10-3185 |
0.41 |
|
| 2010 |
Zhao LC, Kim DY, Le B, Alphs H, Helfand BT, Kan D, Smith ND, Mirkin CA, Thaxton CS, Loeb S, Catalona WJ. 575 NANOTECHNOLOGY PSA MEASUREMENTS CORRELATE WITH PROSTATE CANCER PATHOLOGY AND RESPONSE TO ADJUVANT TREATMENT Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.834 |
0.429 |
|
| 2010 |
Zhang Q, Chen L, Helfand B, Smith N, Zhu J, Javonovic B, Guo Y, Lee C. 392 SUPPRESSION OF PROSTATE CANCER GROWTH BY A NEUTRALIZING ANTI-TRANSFORMING GROWTH FACTOR-BETA (TGF-β) ANTIBODY 1D11 Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.460 |
0.316 |
|
| 2010 |
Chen L, Zhang Q, Helfand B, Zhu J, Smith N, Guo Y, Lee C. 386 ERK ACTIVATION MEDIATES TRANSFORMING GROWTH FACTOR-β INDUCED UP-REGULATION OF DNA METHYLTRANSFERASE IN HUMAN PROSTATE CANCER CELLS Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.454 |
0.381 |
|
| 2010 |
Hofer MD, Helfand BT, Loeb S, O'Brien DC, Kan D, Catalona WJ. 297 ARE NEWLY DESCRIBED PROSTATE CANCER SUSCEPTIBILITY VARIANTS ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS? Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.360 |
0.466 |
|
| 2010 |
Carvalhal G, Loeb S, Kan D, Hofer MD, Casey JT, Helfand BT, Catalona WJ. 287 HOW LONG CAN SURGERY SAFELY BE DELAYED IN MEN WITH LOW-RISK PROSTATE CANCER? Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.349 |
0.43 |
|
| 2010 |
Helfand BT, Loeb S, Hofer MD, Kim R, Cooper PR, Kan D, Catalona WJ. 123 GENETIC VARIANTS SIGNIFICANTLY IMPROVE DETECTION OF PROSTATE CANCER AND ARE ASSOCIATED WITH AGGRESSIVE FEATURES IN PATIENTS WITH A “NORMAL” PSA AND DRE Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.174 |
0.44 |
|
| 2010 |
Meeks JJ, Hofer MD, Helfand BT, Loeb S, Banks JA, Kan D, Catalona WJ. 122 NEW RISK ALLELES IN PATIENTS WITH FAMILIAL AND NON-FAMILIAL PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.173 |
0.393 |
|
| 2010 |
Meeks JJ, Loeb S, Kim R, Kan D, Banks JA, Cooper PR, Helfand BT, Catalona WJ. 854 SCREENING HISTORY OF MEN WITH FATAL PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1610 |
0.441 |
|
| 2010 |
Helfand BT, Fought A, Hofer MD, Kan D, Loeb S, Catalona WJ. 1737 Most Parsimonious Model With Genetic Variants To Evaluate Prostate Cancer Risk The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1585 |
0.434 |
|
| 2010 |
Helfand BT, Kan D, Loeb S, Cooper PR, Le BV, Catalona WJ. 1734 IMPROVED PREDICTION OF PROSTATE BIOPSY RESULTS BY COMBINING PROPSA AND GENETIC RISK MARKERS: PROOF-OF-PRINCIPLE STUDY Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1582 |
0.403 |
|
| 2010 |
Helfand BT, Loeb S, Kan D, Meeks JJ, Le B, Hofer MD, Banks JA, Cooper PR, Catalona WJ. 92 PROSTATE CANCER RISK VARIANTS ASSOCIATED WITH SUSCEPTIBILITY TO OTHER MALIGNANCIES Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.141 |
0.459 |
|
| 2010 |
Helfand BT, Loeb S, Kan D, Catalona WJ. 90 COMPARISON OF 2 DIFFERENT METHODOLOGIES USED TO DETERMINE INTERACTIONS BETWEEN PROSTATE CANCER SUCEPTIBILITY VARIANTS Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.139 |
0.442 |
|
| 2010 |
Zhang Q, Helfand B, Chen L, Qin W, Smith N, Zhu J, Guo Y, Lee C. 680 ADOPTIVE TRANSFER OF PSMA-SPECIFIC, TGF-β INSENSITIVE MEMORY CD8+ T CELLS: SUPPRESSION OF HUMAN PROSTATE CANCER (CAP) Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1079 |
0.363 |
|
| 2009 |
Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. The Urologic Clinics of North America. 36: 443-59, v-vi. PMID 19942044 DOI: 10.1016/J.Ucl.2009.07.004 |
0.359 |
|
| 2009 |
Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, Benediktsdottir KR, Magnusdottir DN, Orlygsdottir G, Jakobsdottir M, Stacey SN, Sigurdsson A, Wahlfors T, Tammela T, Breyer JP, ... ... Helfand BT, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nature Genetics. 41: 1122-6. PMID 19767754 DOI: 10.1038/Ng.448 |
0.391 |
|
| 2009 |
Loeb S, Helfand BT, Kan D, Isaacs WB, Catalona WJ. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? Bju International. 104: 1200-3. PMID 19627283 DOI: 10.1111/J.1464-410X.2009.08656.X |
0.438 |
|
| 2009 |
Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pallari HM, Goldman RD. Introducing intermediate filaments: from discovery to disease. The Journal of Clinical Investigation. 119: 1763-71. PMID 19587451 DOI: 10.1172/Jci38339 |
0.732 |
|
| 2009 |
Pal P, Xi H, Guha S, Sun G, Helfand BT, Meeks JJ, Suarez BK, Catalona WJ, Deka R. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. The Prostate. 69: 1548-56. PMID 19562729 DOI: 10.1002/Pros.20999 |
0.437 |
|
| 2009 |
Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, Kozlowski J, Smith N, Kundu SD, Yang G, Raji AA, Javonovic B, Pins M, Lindholm P, Guo Y, et al. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3557-67. PMID 19447876 DOI: 10.1158/1078-0432.Ccr-08-1656 |
0.362 |
|
| 2009 |
Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology. 74: 177-83. PMID 19428074 DOI: 10.1016/J.Urology.2008.10.062 |
0.454 |
|
| 2009 |
Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, Catalona WJ. Pathological outcomes associated with the 17q prostate cancer risk variants. The Journal of Urology. 181: 2502-7. PMID 19371897 DOI: 10.1016/J.Juro.2009.01.109 |
0.381 |
|
| 2009 |
Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, Catalona WJ. Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. The Journal of Urology. 181: 2515-8; discussion 2. PMID 19371879 DOI: 10.1016/J.Juro.2009.01.102 |
0.456 |
|
| 2009 |
Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, Catalona WJ. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease. Bju International. 104: 304-9. PMID 19239451 DOI: 10.1111/J.1464-410X.2009.08421.X |
0.382 |
|
| 2009 |
Helfand BT, Loeb S, Kan D, Fought AJ, Catalona WJ. Genetic Prostate Cancer Risk Assessment: Common Variants In 9 Genomic Regions Are Associated With Cumulative Prostate Cancer Risk And Aggressive Disease The Journal of Urology. 181: 815-815. DOI: 10.1016/S0022-5347(09)62272-2 |
0.461 |
|
| 2009 |
Okotie OT, Pazona JF, Volpert OV, Kozlowski J, Thaxton CS, Navai N, Helfand BT, Zhao LC, Adley B, Lu Y, Smith ND. NEUROLIGIN 4 ISOFORM Y: A NOVEL MARKER FOR PROSTATE CANCER The Journal of Urology. 181: 657-658. DOI: 10.1016/S0022-5347(09)61844-9 |
0.457 |
|
| 2009 |
Loeb S, Helfand BT, Roehl KA, Kan D, Nadler RB, Catalona WJ. DOES A LOWER PSA VELOCITY THRESHOLD LEAD TO THE DETECTION OF MORE INSIGNIFICANT CANCERS? The Journal of Urology. 181: 645. DOI: 10.1016/S0022-5347(09)61811-5 |
0.319 |
|
| 2009 |
Zhang Q, Jang T, Helfand BT, Zhu LJ, Smith ND, Javonovic B, Lee C. TGF-β-INDUCED EXPRESSION OF VIMENTIN PREDICTS PROSTATE CANCER RECURRENCE WHICH IS INDEPENDENT OF PATHOLOGICAL STAGE Journal of Urology. 181: 399-399. DOI: 10.1016/S0022-5347(09)61133-2 |
0.386 |
|
| 2009 |
Catalona WJ, Jin CH, Roehl KA, Loeb S, Helfand BT, Suarez BK. IN MEN WITH RISING PSA AFTER RADICAL PROSTATECTOMY, 8Q24 PROSTATE CANCER RISK ALLELES HELP PREDICT THREATENING CANCER PROGRESSION AND NEED FOR SALVAGE THERAPY Journal of Urology. 181: 269-269. DOI: 10.1016/S0022-5347(09)60768-0 |
0.447 |
|
| 2009 |
Loeb S, Helfand BT, Kan D, Isaacs WB, Catalona WJ. ARE DIABETES MELLITUS AND CHROMOSOME 17Q12 GENETIC VARIANTS ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS? Journal of Urology. 181: 102-102. DOI: 10.1016/S0022-5347(09)60292-5 |
0.432 |
|
| 2009 |
Helfand BT, Loeb S, Kan D, Fought AJ, Catalona WJ. Prostate Cancer Genetic Variants Can Help Identify Patients With Possibly “Insignificant” Prostate Cancer The Journal of Urology. 181: 101-101. DOI: 10.1016/S0022-5347(09)60288-3 |
0.464 |
|
| 2009 |
Kan D, Helfand BT, Loeb S, Catalona WJ. ASSOCIATION OF PROSTATE CANCER GENETIC RISK ALLELES WITH PROSTATE BIOPSY RESULTS Journal of Urology. 181: 52-52. DOI: 10.1016/S0022-5347(09)60157-9 |
0.431 |
|
| 2009 |
Meeks JJ, Helfand BT, Loeb S, Kan D, Fought AJ, Catalona WJ. First-Degree Family History Of Prostate Cancer And Carrier Status Of Prostate Cancer Risk Alleles The Journal of Urology. 181: 49-49. DOI: 10.1016/S0022-5347(09)60149-X |
0.463 |
|
| 2008 |
Anderson CB, Helfand BT, McVary KT. Holmium laser prostatic resection for patients presenting with acute urinary retention. Bju International. 102: 1623-8. PMID 18710443 DOI: 10.1111/J.1464-410X.2008.07915.X |
0.388 |
|
| 2008 |
Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, Catalona WJ. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. The Journal of Urology. 179: 2197-201; discussion. PMID 18423739 DOI: 10.1016/J.Juro.2008.01.110 |
0.401 |
|
| 2008 |
Loeb S, Roehl KA, Helfand BT, Catalona WJ. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology. 72: 887-91. PMID 18329080 DOI: 10.1016/J.Urology.2007.12.016 |
0.448 |
|
| 2008 |
Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer. The Journal of Urology. 179: 1340-3. PMID 18289590 DOI: 10.1016/J.Juro.2007.11.068 |
0.456 |
|
| 2008 |
Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Blondal T, Jakobsdottir M, Stacey SN, Kostic J, Kristinsson KT, Birgisdottir B, ... ... Helfand BT, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nature Genetics. 40: 281-3. PMID 18264098 DOI: 10.1038/Ng.89 |
0.423 |
|
| 2008 |
Helfand BT, Loeb S, Meeks JJ, Kan D, Gashti SN, Smith ND, Griffin CR, Mondo DM, Catalona WJ. A MULTIPLICATIVE MODEL OF PROSTATE CANCER SUSCEPTIBILITY ALLELES ON 8q24 AND 17q: WHICH COMBINATION IS ASSOCIATED WITH AGGRESSIVE CANCER? Journal of Urology. 179: 708-708. DOI: 10.1016/S0022-5347(08)62061-3 |
0.393 |
|
| 2008 |
Meeks JJ, Helfand BT, Kan D, Smith ND, Mondo DM, Griffin CR, Catalona WJ. FREQUENCY OF 8q24 PROSTATE CANCER SUSCEPTIBILITY ALLELES ACROSS AGE GROUPS OF MEN WITH PROSTATE CANCER Journal of Urology. 179: 423-423. DOI: 10.1016/S0022-5347(08)61240-9 |
0.451 |
|
| 2008 |
Xi H, Pal P, Guha S, Sun G, Meeks JJ, Helfand BT, Suarez BK, Catalona WJ, Deka R. COMMON VARIANTS ON MLH1 GENE AND THEIR ASSOCIATIONS WITH PROSTATE CANCER IN EUROPEAN AMERICANS Journal of Urology. 179: 227-227. DOI: 10.1016/S0022-5347(08)60654-0 |
0.441 |
|
| 2008 |
Pal P, Xi H, Guha S, Sun G, Helfand BT, Meeks JJ, Suarez BK, Catalona WJ, Deka R. GENETIC VARIATION ON 8q24 AND SUSCEPTIBILITY TO PROSTATE CANCER IN CAUCASIAN MEN Journal of Urology. 179: 226-226. DOI: 10.1016/S0022-5347(08)60653-9 |
0.435 |
|
| 2008 |
Meeks JJ, Loeb S, Kan D, Helfand BT, Smith ND, Griffin CR, Catalona WJ. CHARACTERISTICS OF PROSTATE CANCERS DETECTED AT LOW PSA VALUES Journal of Urology. 179: 209-209. DOI: 10.1016/S0022-5347(08)60603-5 |
0.439 |
|
| 2008 |
Helfand BT, Loeb S, Meeks JJ, Kan D, Smith ND, Catalona WJ. DO THE 3 SIGNIFICANT 8q24 PROSTATE CANCER SUSCEPTIBILITY REGIONS PREDICT AGGRESSIVE DISEASE? Journal of Urology. 179: 113-113. DOI: 10.1016/S0022-5347(08)60325-0 |
0.419 |
|
| 2007 |
Helfand BT, Loeb S, Anderson CB, Cashy JP, Meeks JJ, Thaxton CS, Roehl KA, Catalona WJ. 1748: PSA velocity in men with Prostatitis Documented on the Biopsy Specimen or Prostatectomy Specimen Journal of Urology. 177: 581-581. DOI: 10.1016/S0022-5347(18)31936-0 |
0.422 |
|
| 2007 |
Helfand BT, Vyas A, Fine M, Dedhia R, Anderson CB, McVary KT. 1503: Post-Operative PSA Values and PSA Velocity Predict the Presence of Prostate Cancer Following Various Surgical Interventions for Benign Prostatic Hyperplasia (BPH) Journal of Urology. 177: 496-496. DOI: 10.1016/S0022-5347(18)31704-X |
0.438 |
|
| 2007 |
Thaxton CS, Loeb S, Roehl KA, Helfand BT, Meeks JJ, Catalona WJ. 608: PSA Velocity in Screened Versus Referred Men with Prostate Cancer Journal of Urology. 177: 204-204. DOI: 10.1016/S0022-5347(18)30848-6 |
0.435 |
|
| 2007 |
Helfand BT, Loeb S, Cashy JP, Roehl KA, Graif TM, Han M, Catalona WJ. 221: Tumor Characteristics and Treatment Outcomes of Carriers and Noncarriers of the Decode Prostate Cancer Susceptibility Genes Journal of Urology. 177: 74-74. DOI: 10.1016/S0022-5347(18)30486-5 |
0.395 |
|
| 2006 |
Helfand B, Mouli S, Dedhia R, McVary KT. Management of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia With Open Prostatectomy: Results of a Contemporary Series Journal of Urology. 176: 2557-2561. PMID 17085158 DOI: 10.1016/J.Juro.2006.07.143 |
0.41 |
|
| 2006 |
Hillberg L, Zhao Rathje LS, Nyåkern-Meazza M, Helfand B, Goldman RD, Schutt CE, Lindberg U. Tropomyosins are present in lamellipodia of motile cells. European Journal of Cell Biology. 85: 399-409. PMID 16524642 DOI: 10.1016/J.Ejcb.2005.12.005 |
0.503 |
|
| 2005 |
Helfand BT, Chou YH, Shumaker DK, Goldman RD. Intermediate filament proteins participate in signal transduction. Trends in Cell Biology. 15: 568-70. PMID 16213139 DOI: 10.1016/J.Tcb.2005.09.009 |
0.477 |
|
| 2004 |
Helfand BT, Chang L, Goldman RD. Intermediate filaments are dynamic and motile elements of cellular architecture. Journal of Cell Science. 117: 133-41. PMID 14676269 DOI: 10.1242/Jcs.00936 |
0.753 |
|
| 2003 |
Helfand BT, Mendez MG, Pugh J, Delsert C, Goldman RD. A role for intermediate filaments in determining and maintaining the shape of nerve cells. Molecular Biology of the Cell. 14: 5069-81. PMID 14595112 DOI: 10.1091/Mbc.E03-06-0376 |
0.713 |
|
| 2003 |
Helfand BT, Chang L, Goldman RD. The dynamic and motile properties of intermediate filaments. Annual Review of Cell and Developmental Biology. 19: 445-67. PMID 14570577 DOI: 10.1146/Annurev.Cellbio.19.111401.092306 |
0.754 |
|
| 2003 |
Helfand BT, Loomis P, Yoon M, Goldman RD. Rapid transport of neural intermediate filament protein. Journal of Cell Science. 116: 2345-59. PMID 12711702 DOI: 10.1242/Jcs.00526 |
0.504 |
|
| 2002 |
Helfand BT, Mikami A, Vallee RB, Goldman RD. A requirement for cytoplasmic dynein and dynactin in intermediate filament network assembly and organization. The Journal of Cell Biology. 157: 795-806. PMID 12034772 DOI: 10.1083/Jcb.200202027 |
0.507 |
|
| 2001 |
Chou YH, Helfand BT, Goldman RD. New horizons in cytoskeletal dynamics: transport of intermediate filaments along microtubule tracks. Current Opinion in Cell Biology. 13: 106-9. PMID 11163141 DOI: 10.1016/S0955-0674(00)00181-2 |
0.491 |
|
| 2000 |
Prahlad V, Helfand BT, Langford GM, Vale RD, Goldman RD. Fast transport of neurofilament protein along microtubules in squid axoplasm. Journal of Cell Science. 113: 3939-46. PMID 11058081 |
0.393 |
|
| Show low-probability matches. |